ELOSALIC OINTMENT

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

MOMETASONE FUROATE; SALICYLIC ACID

Available from:

MSD PHARMA (SINGAPORE) PTE. LTD.

ATC code:

D07XC03

Dosage:

1 mg/g

Pharmaceutical form:

OINTMENT

Composition:

MOMETASONE FUROATE 1 mg/g; SALICYLIC ACID 50 mg/g

Administration route:

TOPICAL

Prescription type:

Prescription Only

Manufactured by:

SCHERING PLOUGH SA DE CV

Authorization status:

ACTIVE

Authorization date:

2003-02-07

Patient Information leaflet

S-CCDS-MK0887B-OT-042014 

ELOSALIC* Ointment 
Brand of mometasone furoate and salicylic acid 

FOR TOPICAL ADMINISTRATION 

DESCRIPTION: Each gram of ELOSALIC Ointment contains
1 mg of mometasone furoate and 50 mg of 
salicylic acid (mometasone furoate 0.1% and salicylic acid 5% ointment).
ELOSALIC Ointment is a 
white to off-white uniform ointment. Inactive ingredients: hexylene glycol,
propylene glycol 
stearate, white petrolatum, white wax and purified water. 

ACTIONS: Pharmacodynamic Properties: The pharmacodynamic
activity of ELOSALIC Ointment is 
directly related
to its active components, mometasone furoate and salicylic acid,
and its vehicle. 

Like other topical corticosteroids, mometasone furoate has
anti-inflammatory, antipruritic, and 
vasoconstrictive properties. The mechanism of the
anti-inflammatory activity of the topical steroids, 
in general, is unclear.
Corticosteroids, however, are thought to act by the
induction of phospholipase 
A
2
 inhibitory proteins, collectively called lipocortins. It is
postulated that these proteins control the 
biosynthesis of potent mediators of inflammation,
such as prostaglandins and leukotrienes, by 
inhibiting the release of their common precursor arachidonic acid.
Arachidonic acid is released from 
membrane phospholipids by phospholipase A
2
. 

Momethasone furoate is a potent inhibitor of
the in vitro production of three inflammatory 
cytokines that are involved in initiating and maintaining the inflammatory state: interleukin 1 (IL-1), 
interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α). 

Salicylic acid has been shown
to desquamate the stratum corneum while not affecting qualitative or 
quantitative changes in the structure of the viable epidermis. This mechanism of action has been 
attributed to a dissolution of
the intercellular cemen

Summary of Product characteristics

S-CCDS-MK0887B-OT-082017
ELOSALIC* Ointment
Brand of mometasone furoate and salicylic acid
FOR TOPICAL ADMINISTRATION
DESCRIPTION: Each gram of ELOSALIC Ointment contains 1 mg of
mometasone furoate and 50 mg of
salicylic acid (mometasone furoate 0.1% and salicylic acid 5%
ointment). ELOSALIC Ointment is a
white to off-white uniform ointment. Inactive ingredients: hexylene
glycol, propylene glycol
stearate, white petrolatum, white wax and purified water.
ACTIONS: Pharmacodynamic Properties: The pharmacodynamic activity of
ELOSALIC Ointment is
directly related to its active components, mometasone furoate and
salicylic acid, and its vehicle.
Like other topical corticosteroids, mometasone furoate has
anti-inflammatory, antipruritic, and
vasoconstrictive properties. The mechanism of the anti-inflammatory
activity of the topical steroids,
in general, is unclear. Corticosteroids, however, are thought to act
by the induction of phospholipase
A
2
inhibitory proteins, collectively called lipocortins. It is postulated
that these proteins control the
biosynthesis of potent mediators of inflammation, such as
prostaglandins and leukotrienes, by
inhibiting the release of their common precursor arachidonic acid.
Arachidonic acid is released from
membrane phospholipids by phospholipase A
2
.
Momethasone furoate is a potent inhibitor of the in vitro production
of three inflammatory
cytokines that are involved in initiating and maintaining the
inflammatory state: interleukin 1 (IL-1),
interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α).
Salicylic acid has been shown to desquamate the stratum corneum while
not affecting qualitative or
quantitative changes in the structure of the viable epidermis. This
mechanism of action has been
attributed to a dissolution of the intercellular cement substance.
Pharmacokinetics: Absorption: Following a single topical application
of a combination of 3H-
mometasone furoate 0.1% and salicylic acid 5% ointment for 12 hours
without occlusion to psoriatic
lesions, approximately 1.5% of the applied